RAPT Q4 2024 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$54M

Net Income

-$53M

EPS (Diluted)

$-9.12

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$240M

Total Liabilities

$50M

Stockholders' Equity

$190M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$54M	-$33M	-64.0%
Net Income	-$53M	-$31M	-72.5%